Compare · HPQ vs OMCL
HPQ vs OMCL
Side-by-side comparison of HP Inc. (HPQ) and Omnicell Inc. (OMCL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both HPQ and OMCL operate in Computer Manufacturing (Technology), so they compete in similar markets.
- HPQ is the larger of the two at $27.17B, about 16.7x OMCL ($1.62B).
- Over the past year, HPQ is up 6.3% and OMCL is up 7.7% - OMCL leads by 1.4 points.
- Both names hit the wire about 5 times in the past 4 weeks.
- HPQ has more recent analyst coverage (25 ratings vs 24 for OMCL).
- Company
- HP Inc.
- Omnicell Inc.
- Price
- $29.21-1.68%
- $35.63+0.24%
- Market cap
- $27.17B
- $1.62B
- 1M return
- +13.43%
- -12.94%
- 1Y return
- +6.25%
- +7.68%
- Industry
- Computer Manufacturing
- Computer Manufacturing
- Exchange
- NYSE
- NASDAQ
- IPO
- 2001
- News (4w)
- 5
- 5
- Recent ratings
- 25
- 24
HP Inc.
HP Inc. provides personal computing and other access devices, imaging and printing products, and related technologies, solutions, and services in the United States and internationally. The company operates through three segments: Personal Systems, Printing, and Corporate Investments. The Personal Systems segment offers commercial and consumer desktop and notebook personal computers, workstations, thin clients, commercial mobility devices, retail point-of-sale systems, displays and other related accessories, software, support, and services. The Printing segment provides consumer and commercial printer hardware, supplies, solutions, and services, as well as scanning devices. The Corporate Investments segment includes HP Labs and business incubation projects. HP Inc. serves individual consumers, small- and medium-sized businesses, and large enterprises, including customers in the government, health, and education sectors. The company was formerly known as Hewlett-Packard Company and changed its name to HP Inc. in October 2015. HP Inc. was founded in 1939 and is headquartered in Palo Alto, California.
Omnicell Inc.
Omnicell, Inc., together with its subsidiaries, provides medication management automation solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers central pharmacy automation solutions, including automated storage and retrieval systems, such as XR2 Automated Central Pharmacy System, a building block of autonomous pharmacy vision; IV compounding robots and workflow management systems; inventory management software; and controlled substance management systems. It also provides point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; Omnicell Interface Software that offers interface and integration between its medication-use products or supply products, and a healthcare facility's in-house information management systems; and robotic dispensing systems for handling the stocking and retrieval of boxed medications. In addition, the company provides automated systems to help pharmacies in filling its multimed adherence packaging based on individual patient medication orders; single dose automation solutions to fill and label for incoming prescriptions; semi-automated filling equipment for the long-term care institutional pharmacy; and medication blister card packaging and packaging supplies to enhance medication adherence in non-acute care settings. Further, it offers EnlivenHealth Patient Engagement, a web-based nexus of solutions. The company was formerly known as Omnicell Technologies, Inc. and changed its name to Omnicell, Inc. in 2001. Omnicell, Inc. was incorporated in 1992 and is headquartered in Mountain View, California.
Latest HPQ
- Unlock Gaming Potential with Exciting New Gear at HyperX Level Awakening 2026
- Chief Commercial Officer Mcquarrie David P. sold $631,019 worth of shares (21,048 units at $29.98) as part of a pre-agreed trading plan, decreasing direct ownership by 35% to 39,580 units (SEC Form 4)
- Chief Financial Officer Parkhill Karen L converted options into 166,746 shares and covered exercise/tax liability with 69,173 shares, increasing direct ownership by 96% to 199,707 units (SEC Form 4) to satisfy withholding obligation
- HP Inc. to Announce Third Quarter Fiscal 2026 Earnings on August 26, 2026 and to Attend Upcoming Investor Conferences
- Chief Commercial Officer Mcquarrie David P. sold $587,871 worth of shares (21,048 units at $27.93) as part of a pre-agreed trading plan, decreasing direct ownership by 26% to 60,628 units (SEC Form 4)
- Chief Commercial Officer Mcquarrie David P. sold $294,462 worth of shares (10,524 units at $27.98) as part of a pre-agreed trading plan, decreasing direct ownership by 11% to 81,676 units (SEC Form 4)
- Global Controller and CAO Grewal Manpreet converted options into 22,637 shares and covered exercise/tax liability with 5,513 shares (SEC Form 4) to satisfy tax liability
- HP Inc. Launches Frontier Strategic Partnership with OpenAI to Fuel Customer-Facing Experiences and Transform Internal Operations
- HP Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Chief Commercial Officer Mcquarrie David P. sold $259,732 worth of shares (10,524 units at $24.68) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 92,200 units (SEC Form 4)
Latest OMCL
- EVP&CHIEF LEGAL/ADMIN OFFICER Manley Corey J covered exercise/tax liability with 4,025 shares, decreasing direct ownership by 4% to 108,985 units (SEC Form 4)
- VP, Chief Accounting Officer Nutt Brian H. covered exercise/tax liability with 937 shares, decreasing direct ownership by 4% to 22,266 units (SEC Form 4)
- President & COO Njoku Nnamdi covered exercise/tax liability with 3,670 shares and sold $113,609 worth of shares (3,083 units at $36.85) as part of a pre-agreed trading plan, decreasing direct ownership by 4% to 161,224 units (SEC Form 4)
- CHAIRMAN, CEO Lipps Randall A covered exercise/tax liability with 12,350 shares, decreasing direct ownership by 2% to 511,096 units (SEC Form 4)
- SEC Form 10-Q filed by Omnicell Inc.
- EnlivenHealth Highlights VaxReach Ahead of ThoughtSpot 2026 — Designed to Help Pharmacies Strengthen Communities Through Vaccination
- Omnicell Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Omnicell Announces Second Quarter 2026 Financial Results
- CHAIRMAN, CEO Lipps Randall A sold $470,000 worth of shares (10,000 units at $47.00) as part of a pre-agreed trading plan (SEC Form 4)
- Omnicell to Release Second Quarter 2026 Financial Results on July 30, 2026